Frost; Philip

Patent Applications and Registrations

Patent applications and USPTO patent grants for Frost; Philip.The latest application filed is for "use of a receptor-type kinase modulator for treating polycystic kidney disease".

Company Profile

0.15.12

Frost; Philip - Rockville MD
Frost; Philip - Morris Township NJ
Frost; Philip - Miami Beach FL

*profile and listings may contain filings by different individuals or companies with the same name. Review application materials to confirm ownership/assignment.

Patent Activity

Patent	Date
Use of a receptor-type kinase modulator for treating polycystic kidney disease Grant 9,956,221 - Frost , et al. May 1, 2	2018-05-01
Use of a Receptor-Type Kinase Modulator for Treating Polycystic Kidney Disease App 20160367555 - Frost; Philip ; et al.	2016-12-22
Use of a receptor-type kinase modulator for treating polycystic kidney disease Grant 9,364,479 - Frost , et al. June 14, 2	2016-06-14
Use of a Receptor-Type Kinase Modulator for Treating Polycystic Kidney Disease App 20130217711 - Frost; Philip ; et al.	2013-08-22
Substituted 3-cyanoquinolines Grant RE42,376 - Wissner , et al. May 17, 2	2011-05-17
Use of CCI-779 as an antineoplastic agent Grant 7,781,446 - Dukart , et al. August 24, 2	2010-08-24
Method for the treatment of polycystic kidney disease Grant 7,488,754 - Frost , et al. February 10, 2	2009-02-10
Use of CCI-779 as an antineoplastic agent App 20070142425 - Dukart; Gary ; et al.	2007-06-21
Use of CCI-779 as an antineoplastic agent Grant 7,189,735 - Dukart , et al. March 13, 2	2007-03-13
Method for the treatment of polycystic kidney disease App 20060079515 - Frost; Philip	2006-04-13
Treatment of aromatase inhibitor therapy-related osteoporosis App 20050272717 - Jenkins, Simon N. ; et al.	2005-12-08
Use of a combination of an epidermal growth factor receptor kinase inhibitor and cytotoxic agents for treatment and inhibition of cancer App 20050026933 - Greenberger, Lee ; et al.	2005-02-03
Method for the treatment of polycystic kidney disease App 20040063672 - Frost, Philip ; et al.	2004-04-01
Use of CCI-779 as an antineoplastic agent App 20030153593 - Dukart, Gary ; et al.	2003-08-14
Method of treating estrogen receptor positive carcinoma Grant 6,511,986 - Zhang , et al. January 28, 2	2003-01-28
Method of treating or inhibiting colonic polyps and colorectal cancer Grant 6,432,979 - Frost , et al. August 13, 2	2002-08-13
Use of CCI-779 as an antineoplastic agent App 20020091137 - Dukart, Gary ; et al.	2002-07-11
Method of treating or inhibiting colonic polyps Grant 6,384,051 - Frost , et al. May 7, 2	2002-05-07
Method of treating estrogen receptor positive carcinoma App 20020045638 - Zhang, Yixian ; et al.	2002-04-18
Method of treating or inhibiting colonic polyps Grant 6,323,209 - Frost November 27, 2	2001-11-27
Substituted 3-cyanoquinolines Grant 6,297,258 - Wissner , et al. October 2, 2	2001-10-02
Substituted 3-cyanoquinolines Grant 6,288,082 - Wissner , et al. September 11, 2	2001-09-11
Method of treating polycystic kidney disease Grant 5,929,080 - Frost July 27, 1	1999-07-27
Apparatus For Pressure-administering Medicaments Grant 3,625,208 - Frost , et al. December 7, 1	1971-12-07

Company Registrations

SEC

0001319666

Frost Philip

uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.

While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.

All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.